Correlation Between Vaxcyte and Travere Therapeutics

Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Travere Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Travere Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vaxcyte and Travere Therapeutics, you can compare the effects of market volatilities on Vaxcyte and Travere Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Travere Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Travere Therapeutics.

Diversification Opportunities for Vaxcyte and Travere Therapeutics

0.07

Correlation Coefficient

Vaxcyte  Travere Therapeutics

Significant diversification

The 3 months correlation between Vaxcyte and Travere is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Travere Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Travere Therapeutics and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Travere Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Travere Therapeutics has no effect on the direction of Vaxcyte i.e., Vaxcyte and Travere Therapeutics go up and down completely randomly.

Pair Corralation between Vaxcyte and Travere Therapeutics

Given the investment horizon of 90 days Vaxcyte is expected to under-perform the Travere Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Vaxcyte is 1.21 times less risky than Travere Therapeutics. The stock trades about -0.07 of its potential returns per unit of risk. The Travere Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  1,732  in Travere Therapeutics on December 29, 2024 and sell it today you would earn a total of  236.00  from holding Travere Therapeutics or generate 13.63% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Vaxcyte  vs.  Travere Therapeutics

Vaxcyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Vaxcyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Travere Therapeutics

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Travere Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Travere Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vaxcyte and Travere Therapeutics

The main advantage of trading using opposite Vaxcyte and Travere Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Travere Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Travere Therapeutics will offset losses from the drop in Travere Therapeutics' long position.

The idea behind Vaxcyte and Travere Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.